Skip to main content

Curium strengthens its PET manufacturing capacity and expands European footprint with the acquisition of Nucleis

Written by Customer Service on . Posted in Mergers And Acquisitions.

The acquisition of Nucleis will:

  • Enhance Curium’s PET manufacturing capacity and radiopharmaceutical distribution network of 32 PET sites in Western Europe
  • Improve reliability and accessibility of life-saving PET diagnostics for patients in Benelux and Germany
  • Expand CDMO capabilities to support the development of innovative PET tracers in oncology, neurology, and cardiology

PARIS, April 10, 2025 (GLOBE NEWSWIRE) — Curium, a world leader in nuclear medicine, announced today that it has completed the acquisition of Nucleis, a specialist in GMP manufacturing and distribution of PET radiopharmaceutical drugs.

Founded in 2017 as a spin-off from the University of Liège (Cyclotron Research Center, Belgium), Nucleis has established itself as a key player in PET imaging radiopharmaceuticals. Nucleis manufactures and distributes FDG in the Benelux region and offers CDMO services to third-party nuclear medicine players to produce innovative tracers.

The completion of this transaction marks an additional milestone in Curium’s strategic growth in the PET segment, reinforcing its commitment to nuclear medicine innovation and ensuring greater accessibility to cutting-edge PET diagnostics for patients across Europe.

The acquisition will add manufacturing capacity to meet the growing demand for F-18 tracers and it will reinforce the reliability of Curium’s supply chain, ensuring consistent delivery of critical radiopharmaceuticals to healthcare providers and patients across the Benelux region.

Through this acquisition, Curium will accelerate the development of life-changing diagnostics in oncology, neurology, and cardiology. The company will expand production of innovative radiotracers by adding Curium’s proprietary tracers to Nucleis’ portfolio, and strengthening partnerships with CDMO customers.

Benoit Woessmer, CEO of Curium EU, commented:
“We are thrilled to welcome Nucleis into the Curium family. This acquisition is an additional step in expanding our PET footprint and strengthening our capabilities in the European nuclear medicine market. By combining our resources with the Nucleis team, we will further enhance the availability of high-quality PET diagnostics for patients.”

Fabrice Giacomelli, Former CEO of Nucleis, added:
“Joining Curium marks an exciting new chapter for Nucleis. We will benefit from Curium’s expertise and infrastructure to accelerate the development and delivery of next-generation PET tracers, benefiting patients and healthcare providers alike.”

About Curium

Curium is a world leader in nuclear medicine. We develop, manufacture, and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence, and unparalleled service.

With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive materials researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. To learn more, visit www.curiumpharma.com

A spin-off from the University of Liège

Nucleis is a spin-off from the University of Liège (Cyclotron Research Center – Belgium) created to outsource the GMP manufacturing and distribution of PET (Positron Emission Tomography) radiopharmaceutical drugs.

The company was created in June 2017 with the transfer of the business unit (team, pharmaceutical certifications, CMO (Contract Manufacturing Organization) contracts and dedicated manufacturing facilities) from CRC (Cyclotron Research Center) and benefits from over 15 years of experience.

For more information:
communications@curiumpharma.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.